SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharma News Only (pfe,mrk,wla, sgp, ahp, bmy, lly) -- Ignore unavailable to you. Want to Upgrade?


To: chirodoc who wrote (1083)11/20/1998 3:33:00 AM
From: Anthony Wong  Read Replies (2) | Respond to of 1722
 
The 11/30 Forbes Magazine "Streetwalker" article on AHP's second look at MTC:

The next shoe . . .

It may not be over between American Home
Products and Monsanto. In October the pair
made headlines by canceling their proposed $35
billion merger—a deal that would have had
American Home buying Monsanto for stock and
winding up with 65% control of the company.
The seeming problem was bad chemistry between
the prospective cochairmen, American Home's
chief executive, John Stafford, and Monsanto's
Robert Shapiro.

But Streetwalker now hears that Stafford, having
gotten a closer look at Monsanto and the
promising new drugs in the pipeline of its G.D.
Searle subsidiary, likes what he sees even more.
He's said to be planning to launch an unfriendly
bid for Monsanto that would, among other things,
give Shapiro the gate.

Monsanto was recently at $39.19, 22% below
where it closed the day before the merger was
canceled and 38% below its late August high.
American Home will probably need to pay over
$50 in a hostile bid.

Streetwalker also hears that Monsanto has
reopened talks with DuPont, with which it
discussed a partnership between the two
companies' life sciences operations a year ago.
DuPont could wind up as a convenient white
knight. Buy Monsanto, target price: $55.
–THOMAS JAFFE
forbes.com

Bloomberg's story of 11/15 on the article:
Message 6427838